SUCCINATE-CONTAINING ANTIHYPOXANTS IN THE TREATMENT OF ASTHENIC DISORDERS

Authors

  • Galina Viktorovna Buznik Department of Pharmacology FGBVOU "Military Medical Academy them. CM. Kirov, Ministry of Defense of the Russian Federation, St. Petersburg, Department of Neuropharmacology them. S.V. Anichkov Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"
  • Pyotr Dmitrievich Shabanov Department of Pharmacology FGBVOU "Military Medical Academy them. CM. Kirov, Ministry of Defense of the Russian Federation, St. Petersburg, Department of Neuropharmacology them. S.V. Anichkov Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"

Keywords:

asthenic syndrome, neurometabolic therapy, antihypoxants, succinic acid.

Abstract

In patients with asthenic disorders (134 surgical patients who had a concomitant injury, 116 neurological patients who had a closed craniocerebral injury, 142 patients with neurotic and stress-related disorders, 148 suffering from alcoholism), the clinical features of the asthenic symptom complex were studied by methods of clinical and psychological interviews with using numerous scales to assess  the emotional state, cognitive processes, attitudes towards the disease, well-being, mood and activity, in order to divide them into subgroups (randomization) and carry out pharmacological correction of asthenic manifestations with the help of succinate-containing metabolic protectors that have the properties of antihypoxants (Mexicor, Cytoflavin, Metaprot plus). The work proves that the asthenic symptom complex undergoes reduction when pharmacological substances of the neurometabolic type of action are prescribed, mainly containing succinic acid in their structure (Mexicor, Cytoflavin, Metaprot plus). These drugs have advantages in efficiency in comparison with succinate-free metabolic protectors (emoxipin, riboxin, metaprot).

References

Бузник, Г.В. Сравнение эффективности лечения астенических нарушений вследствие невротических и связанных со стрессом расстройств феназепамом и сукцинатсодержащими метаболическими протекторами / Г.В. Бузник, П.Д. Шабанов // Вестник Смоленской гос. мед. академии. 2020. Т.17, No3. С.31–40.

Бузник, Г.В. Фармакологическая реабилитация больных алкоголизмом в постабстинентном периоде метаболическими средствами, содержащими и не содержащими сукцинат / Г.В. Бузник, В.В. Востриков, П.Д. Шабанов // Вестник Смоленской гос. мед. академии. 2020. Т.17, No4. С.25–34.

Бузник, Г.В. Фармакотерапия нарушений астенического спектра у хирургических пациентов и пострадавших с сочетанными травмами с помощью сукцинатсодержащих препаратов / Г.В. Бузник, П.Д. Шабанов // Вестник Смоленской гос. мед. академии. 2020. Т.17, No3. С.17–30.

Родичкин П.В. Эффективность профессиональной деятельности спортсменов в зависимости от полиморфизма генов регуляторов метаболизма и фармакологической поддержки / П.В. Родичкин, Г.В. Бузник, 32 Известия НАН КР, 2022, No6 А.О. Пятибрат, П.Д. Шабанов // Теория и практика физич. культуры. 2018. No 8. С.24-27 [Rodichkin, P.V. Professional athletic performance efficiency versus metabolism controlling gene polymorphism and pharmacological support / P.V. Rodichkin, G.V. Buznik, A.O. Pyatibrat, P.D. Shabanov // Theory and Practice of Physical Culture. 2018. N8. P.7].

Шабанов П.Д. Фармакотерапия астенического синдрома средствами метаболической терапии: реко- мендации для врачей / П.Д. Шабанов, Г.В. Бузник, А.А. Байрамов. СПб.: ВМедА, 2020. 56 с.

Fernández, A.A. Chronic fatigue syndrome: aetiology, diagnosis and treatment / A.A. Fernández, Á.P. Martín, M.I. Martínez et al. // BMC Psychiatry. –2009. – Vol. 9, Suppl. 1. – P. S1.

Larun, L. Exercise therapy for chronic fatigue syndrome (individual patient data) / L. Larun, J. Odgaard- Jensen, K.G. Brurberg et al. // Cochrane Database Syst. Rev. – 2018. – Vol. 2018, N 12. – CD011040.

Voronina, T.A. Combined administration of mexidol with known medicines / T.A. Voronina, E.A. Ivanova // Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova. – 2019. – Vol. 119, N 4. – P. 115–124.

Xiao, Z. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial / Z. Xiao, L. Hu, J. Lin et al. // Trials. – 2020. – Vol. 21. – P. 94.

Zarubina, I. V. Antihypoxic and antioxidant effects of exogenous succinic acid and aminothiol succinate-containing antihypoxants / I.V. Zarubina, M.V. Lukk, P.D. Shabanov// Bull. Exp. Biol. Med. – 2012. – Vol. 153, N

– P. 336–339.

Published

2022-09-20

Issue

Section

СЕКЦИЯ ГИПОКСИЯ: МЕХАНИЗМЫ КОМПЕНСАЦИИ И АДАПТАЦИИ